- $288.68bn
- $313.21bn
- $54.07bn
Press Digest: Wall Street Journal - July 8
AstraZeneca secures ex-China license for Sino Biopharmaceutical's experimental COPD drug (updated)
Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion
Brief: Sino Biopharmaceutical Enters Exclusive License Agreement With Astrazeneca For TQC3721
Factbox: Race to launch weight-loss pills heats up as smaller players advance
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Kailera Therapeutics up after weight-loss drug meets main goal of late-stage trials in China
Kailera Therapeutics up after weight-loss drug meets main goal of late-stage trials in China
HSBC says European healthcare can benefit if AI, tech weaken
Europe Research Roundup: Antofagasta, GSK, Swedbank
AstraZeneca signs CSPC China deal for experimental kidney disease drugs (updated)
China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug
Brief: CSPC Pharmaceutical Enters Collaboration, Option & License Agreement With Astrazeneca For siRNA Drugs
HK-listed Abbisko hits 7-week peak on AstraZeneca tie-up
Brief: Abbisko Therapeutics And Astrazeneca Enter A Strategic Collaboration
Brief: AstraZeneca Says CHMP Recommends Datroway For Approval In EU As 1st-Line Treatment For Metastatic TNBC
Enhertu approved in EU for HER2+ solid tumours
Brief: Astrazeneca Reports Favourable Safety Profile For Efzimfotase Alfa In Phase III HPP Trials
US military requires flu vaccine for some after outbreak in Texas training center